Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
$3.66
+2.1%
$2.66
$1.94
$5.65
$192.96M0.17365,762 shs107,731 shs
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$6.12
+0.5%
$5.84
$4.95
$12.83
$436.86M0.92729,022 shs48,724 shs
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$8.04
+3.5%
$8.46
$7.10
$21.79
$305.90M0.04130,527 shs17,891 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$4.92
+6.6%
$4.38
$3.55
$16.11
$223.48M0.53311,325 shs89,110 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
+1.13%+7.19%+46.12%+10.49%-5.91%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
+0.16%-0.65%-4.09%+12.36%-20.18%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
+0.91%+1.04%-12.40%-35.14%-51.86%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
+4.76%+12.68%+9.22%-14.76%-61.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
3.7734 of 5 stars
3.51.00.04.22.61.70.6
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
2.2916 of 5 stars
0.03.00.00.02.50.83.1
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
2.9438 of 5 stars
3.62.00.00.03.31.71.3
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
3.7456 of 5 stars
4.42.00.00.03.04.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
3.00
Buy$14.00283.04% Upside
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
0.00
N/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.25
Buy$25.67219.24% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.82
Moderate Buy$16.10227.04% Upside

Current Analyst Ratings Breakdown

Latest YMAB, SCPH, TRDA, and SIGA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00 ➝ $18.00
5/20/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/19/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
4/22/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00
3/31/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/21/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $12.00
3/20/2025
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $12.00
3/20/2025
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
3/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $18.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
$41.98M4.60N/AN/A$1.04 per share3.51
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$120.33M3.63$0.97 per share6.34$2.77 per share2.21
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$172.22M1.77N/AN/A$7.26 per share1.11
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$88.66M2.51N/AN/A$2.32 per share2.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
-$54.81M-$1.91N/AN/AN/A-264.60%-244.93%-68.56%8/13/2025 (Estimated)
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$68.07M$0.675.104.90N/A49.33%49.06%38.72%8/7/2025 (Estimated)
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$6.68M$0.815.07N/AN/A25.53%16.11%10.39%8/12/2025 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$21.43M-$0.64N/AN/AN/A-28.22%-24.61%-18.49%8/11/2025 (Estimated)

Latest YMAB, SCPH, TRDA, and SIGA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million
5/13/2025Q1 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million
5/8/2025Q1 2025
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A-$0.01N/A-$0.01N/A$7.04 million
5/8/2025Q1 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million
3/19/2025Q4 2024
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 million
3/11/2025Q4 2024
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A$0.63N/A$0.63N/A$81.40 million
3/4/2025Q4 2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/AN/AN/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A

Latest YMAB, SCPH, TRDA, and SIGA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/8/2025
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
special$0.604/29/20254/29/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
1.66
8.08
6.89
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A
8.10
5.32
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/A
6.59
6.59
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
3.92
3.54

Institutional Ownership

CompanyInstitutional Ownership
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
89.52%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
55.40%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
86.39%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
5.52%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
1.54%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
8.11%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
22.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
3052.79 million47.28 millionOptionable
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
4071.44 million70.31 millionOptionable
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
11037.95 million34.58 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.28 million34.71 millionOptionable

Recent News About These Companies

HC Wainwright Brokers Reduce Earnings Estimates for YMAB

New MarketBeat Followers Over Time

Media Sentiment Over Time

scPharmaceuticals stock logo

scPharmaceuticals NASDAQ:SCPH

$3.66 +0.08 (+2.09%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

SIGA Technologies stock logo

SIGA Technologies NASDAQ:SIGA

$6.12 +0.03 (+0.49%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Entrada Therapeutics stock logo

Entrada Therapeutics NASDAQ:TRDA

$8.04 +0.27 (+3.47%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$4.92 +0.30 (+6.56%)
As of 11:47 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.